Gilead Gives Up On Galapagos's Filgotinib In RA
Belgian Biotech's Stock Battered
A disappointing meeting with the FDA means "we no longer see a viable path to US approval in this indication,” said Gilead CEO Daniel O'Day, as Galapagos assumes sole responsibility for the commercialization of the JAK inhibitor in Europe.
You may also be interested in...
Analysts are scratching their heads over what direction the Belgian biotech will take in the coming months and years, with all eyes on an R&D day in October.
The Belgian biotech's president, Bart Filius, tells Scrip that exiting the metabolic disease and osteoarthritis space and focusing on inflammation makes sense to "bring a bit more balance in terms of risk into our portfolio."
After a difficult spell for the Belgian biotech, positive interim data from two key studies looking at testicular toxicity concerns over filgotinib suggest a pathway for potential future US approval of the Gilead-partnered JAK inhibitor for IBD.